New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 23, 2013
04:55 EDTGSK, GSK, GSK, IRWD, IRWD, IRWD, PFE, PFE, PFE, MRK, MRK, MRK, REGN, REGN, REGN, LLY, LLY, LLY, BMY, BMY, BMY, ALNY, ALNY, ALNY, LIFE, LIFE, LIFE, BIIB, BIIB, BIIB, AZN, AZN, AZN, SCLN, SCLN, SCLNElsevier Business Intelligence to hold a conference
Pharmaceutical Strategy Conference is being held in New York on September 23-25.
News For GSK;AZN;BIIB;LIFE;ALNY;BMY;LLY;REGN;MRK;PFE;IRWD;SCLN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
November 10, 2014
07:19 EDTREGNCredit Suisse to hold a conference
Subscribe for More Information
07:08 EDTIRWDbluebird bio names James DeTore as CFO, treasurer
Subscribe for More Information
November 9, 2014
18:58 EDTMRKMerck presents interim data from C-SWIFT study
Merck announced the presentation of interim data from the C-SWIFT study exploring the potential of a candidate triple-therapy regimen consisting of the fixed-dose combination of grazoprevir/elbasvir , the company’s investigational NS3/4A protease inhibitor and NS5A inhibitor, in combination with sofosbuvir, a nucleotide inhibitor for the treatment of chronic hepatitis C virus, HCV, infection. Preliminary findings in treatment-naïve HCV genotype 1- infected non-cirrhotic patients, following six and four weeks of treatment, and patients with cirrhotic disease, following eight and six weeks of treatment, will be presented by Dr. Eric Lawitz, vice president, scientific and research development, The Texas Liver Institute, San Antonio, TX and C-SWIFT lead investigator. This poster presentation is part of a late-breaking abstract session at the 65th American Association for the Study of Liver Diseases, AASLD, Annual Meeting, also known as The Liver Meeting. “These interim data provide a compelling proof-of-concept for the potential of an eight- or six-week triple therapy course in treatment-naive patients with genotype 1 disease, including cirrhotic patients,” said Dr. Lawitz. “These findings will inform the design of larger studies aimed at understanding the potential of short-duration triple therapy across multiple patient types.”
15:45 EDTBMYBristol-Myers announces daclatasvir data from the UNITY trial program
Subscribe for More Information
14:09 EDTALNYAlnylam management to meet with Needham
Subscribe for More Information
12:40 EDTBMYBristol-Myers announces data from ALLY trial investigating daclatasvir
Subscribe for More Information
11:45 EDTBMYBristol-Myers announces data from the UNITY trial program
Subscribe for More Information
November 7, 2014
20:27 EDTALNYAlnylam management to meet with Piper Jaffray
Meeting to be held in New York on November 12 hosted by Piper Jaffray.
November 6, 2014
15:13 EDTBMY, MRK, ALNYAmerican Association for Study of Liver Diseases to hold a meeting
Subscribe for More Information
09:59 EDTIRWDOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: ANSYS (ANSS) downgraded to Hold from Buy at Benchmark Co.... AcelRx (ACRX) downgraded to Neutral from Buy at Mizuho... American Eagle Energy (AMZG) downgraded to Market Perform from Outperform at Northland... American Electric (AEP) downgraded to Market Perform from Outperform at Wells Fargo... Blucora (BCOR) downgraded to Market Perform from Outperform at Barrington... ChemoCentryx (CCXI) downgraded to Market Perform at Cowen... Coeur Mining (CDE) downgraded to Sell from Hold at Deutsche Bank... Cornerstone OnDemand (CSOD) downgraded to Equal Weight from Overweight at Stephens... Cott Corp. (COT) downgraded to Hold from Buy at Stifel... Dassault Systemes (DASTY) downgraded to Neutral from Buy at Citigroup... Duke Energy (DUK) downgraded at Evercore ISI... Enphase Energy (ENPH) downgraded to In-Line from Outperform at Imperial Capital... Fiesta Restaurant (FRGI) downgraded to Neutral from Buy at Longbow... Fox Factory (FOXF) downgraded to Neutral from Outperform at RW Baird... Genworth (GNW) downgraded to Neutral from Buy at Compass Point... Hormel Foods (HRL) downgraded to Market Perform from Outperform at BMO Capital... IntercontinentalExchange (ICE) downgraded to Hold from Buy at Deutsche Bank... Ironwood (IRWD) downgraded to Sell from Hold at Cantor... Lloyds Banking (LYG) downgraded to Market Perform from Outperform at Bernstein... Meridian Bioscience (VIVO) downgraded to Neutral from Outperform at RW Baird... Neenah Paper (NP) downgraded to Neutral from Buy at DA Davidson... Philip Morris (PM) downgraded to Underperform from Outperform at CLSA... ProAssurance (PRA) downgraded to Market Perform from Outperform at Raymond James... Rex Energy (REXX) downgraded to Neutral from Outperform at RW Baird... S&T Bancorp (STBA) downgraded to Neutral from Buy at Guggenheim... Solazyme (SZYM) downgraded to Market Perform from Outperform at Cowen... Sykes Enterprises (SYKE) downgraded to Neutral from Outperform at RW Baird... Tangoe (TNGO) downgraded to Hold from Buy at Stifel... Web.com (WWWW) downgraded to Neutral from Overweight at JPMorgan... WesBanco (WSBC) downgraded to Neutral from Buy at Guggenheim... Wisconsin Energy (WEC) downgraded to Market Perform from Outperform at Wells Fargo.
09:36 EDTPFEGlycoMimetics announces presentation of GMI-1271, rivipansel
Subscribe for More Information
09:12 EDTMRKMerck to present KEYTRUDA data
Subscribe for More Information
07:43 EDTBIIBIsis Pharmaceuticals earns $10M milestone payment from Biogen
Subscribe for More Information
07:27 EDTMRKBIND announces agreement with Merck to develop Accurin nanomedicines
Subscribe for More Information
06:39 EDTIRWDIronwood downgraded to Sell from Hold at Cantor
Cantor Fitzgerald downgraded Ironwood to Sell citing potential for downside from increased R&D expense in 2015 and possible additional financing needs. The firm lowered its price target for shares to $10 from $11.
06:35 EDTAZN, PFEAstraZeneca CEO says tax revisions cripple new Pfizer offer, Reuters says
Subscribe for More Information
05:51 EDTAZNAstraZeneca targets 2015 EPS to be no less than low end of 2014 range
AstraZeneca said, "For 2015, the Company plans to continue to selectively invest in its growth platforms and accelerating pipeline while managing overall costs. Assuming current exchange rates, the Company is targeting Core EPS for 2015 to be no less than the lower end of the range of the upgraded guidance for Core EPS for 2014 at actual exchange rates. Guidance for 2015 is expected to be provided with 2014 results on 5 February 2015."
05:50 EDTAZNAstraZeneca raises 2014 revenue growth outlook to low single digits at CER
AstraZeneca said 2014 revenue is now expected to increase in low single digits at CER, an upgrade to its previous guidance for revenue to be in line with 2013 at CER. The guidance assumes no U.S. Nexium generic in 2014. It added, "In light of the increase in revenue expectations for the year, the Company is accelerating its investments in its growth platforms and expanding pipeline. Core EPS for 2014 is now expected to decrease at around 10% at CER; better than anticipated in previous guidance. In addition, Core EPS for 2014 at actual exchange rates is expected to be impacted negatively by currency by around 5%, assuming current exchange rates."
05:49 EDTAZNAstraZeneca reports Q3 core EPS $1.05, consensus $1.04
Subscribe for More Information
05:37 EDTAZNAegerion acquires Myalept from AstraZeneca for $325M
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use